Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Kasaian
Marion Kasaian, Charlestown, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20100223685 | IL-21 RECEPTOR KNOCKOUT ANIMAL AND METHODS OF USE THEREOF - A transgenic non-human mammal with a disruption in its IL-21 receptor gene is provided, along with methods of using the transgenic non-human mammal. | 09-02-2010 |
Marion T. Kasaian, Cambridge, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20090098142 | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders - Methods and compositions for treating and/or monitoring treatment of IL-13-associated disorders or conditions are disclosed. | 04-16-2009 |
| 20090274705 | IL-13 BINDING AGENTS - Agents (e.g., antibodies and fragments thereof) that bind specifically to IL 13 and modulate the ability of IL-13 to interact with IL-13 receptors and signaling mediators are disclosed. | 11-05-2009 |
| 20100129360 | ANTIBODIES AGAINST HUMAN INTERLEUKIN-13 AND USES THEREFOR - This application relates to antibodies, e.g., humanized antibodies, and antigen-binding fragments thereof, that bind to interleukin-13 (IL-13), in particular, human IL-13, and their uses in regulating immune responses mediated by IL-13. The antibodies disclosed herein are useful in diagnosing, preventing, and/or treating a subject, e.g., a human patient, one or more IL-13-associated disorders, e.g., respiratory disorders (e.g., asthma); atopic disorders (e.g., allergic rhinitis); inflammatory and/or autoimmune conditions of the skin (e.g., atopic dermatitis), and gastrointestinal organs (e.g., inflammatory bowel diseases (IBD)), as well as fibrotic and cancerous disorders. | 05-27-2010 |
Marion T. Kasaian, Charlestown, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20080241098 | ANTAGONIZING INTERLEUKIN-21 RECEPTOR ACTIVITY - Methods and compositions for inhibiting interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using antagonists of IL-21 or IL-21 receptor (“IL-21R” or “MU-1”), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating, ameliorating or preventing autoimmune or inflammatory disorders, including, e.g., inflammatory bowel disease (IBD), rheumatoid arthritis (RA), transplant/graft rejection, psoriasis, asthma, fibrosis, and systemic lupus erythematosus (SLE). | 10-02-2008 |